Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Terminated 2Unknown 1Completed 1Active not recruiting 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Colorectal Neoplasms 8Sarcoma, Ewing 3Osteosarcoma 3Thyroid Neoplasms 1Solid Malignant Tumors 1Rectal Neoplasms 1Pancreatic Neoplasms 1Neoplasm Metastasis 1Lung Neoplasms 1Gastrointestinal Stromal Tumors 1Esophageal Neoplasms 1Chondrosarcoma 1Chondroma 1Carcinoma, Hepatocellular 1Carcinoma 1Breast Neoplasms 1Bone Neoplasms 1Advanced Colorectal Cancer 1Advanced Biliary Tract Cancer 1Adenocarcinoma 1

Interventions

pembrolizumab 4Oxaliplatin 4zolbetuximab 2camrelizumab 2apatinib 2S 1 (combination) 2Paclitaxel 2Nivolumab 2trifluridine tipiracil drug combination 1trastuzumab deruxtecan 1tislelizumab 1tepotinib 1relugolix 1regorafenib 1lenvatinib 1durvalumab 1dabrafenib 1cemiplimab 1cabazitaxel 1alpha-2'-deoxythioguanosine 1X-Rays 1Vinorelbine 1Trifluridine 1Surveys and Questionnaires 1Ramucirumab 1Radiotherapy, Intensity-Modulated 1Radiotherapy 1Radiosurgery 1Radiation 1Proton Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Adenocarcinoma × regorafenib × Clear all
NCT04879368 2025-07-17

INTEGRATEIIb

Australasian Gastro-Intestinal Trials Group

Phase 3 Active not recruiting
450 enrolled
Tumor-Agnostic

Adenocarcinoma, Carcinoma, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡